The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Catalytic topoisomerase II inhibitors in cancer therapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structure and mechanism of DNA topoisomerase II
Berger, J. M., Gamblin, S. J., Harrison, S. C., & Wang, J. C. (1996) · Nature · doi:10.1038/379225a0 · Cited by 859
Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II
Drake, F. H., Hofmann, G. A., Bartus, H. F., Mattern, M. R., Crooke, S. T., & Mirabelli, C. K. (1989) · Biochemistry · doi:10.1021/bi00446a029 · Cited by 410
Resistance mechanisms associated with altered intracellular distribution of anticancer agents
Larsen, A. K., Escargueil, A. E., & Skladanowski, A. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00073-x · Cited by 369
Self-citationRoca, J., Ishida, R., Berger, J. M., Andoh, T., & Wang, J. C. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.5.1781 · Cited by 348
A topoisomerase II-dependent G2 cycle checkpoint in mammalian cells
Downes, C. S., Clarke, D. J., Mullinger, A. M., Giménez-Abián, J. F., Creighton, A. M., & Johnson, R. T. (1994) · Nature · doi:10.1038/372467a0 · Cited by 317
Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives.
Tanabe, K., Ikegami, Y., Ishida, R., & Andoh, T. (1991) · PubMed · Cited by 292
Swain, S. M., Whaley, F. S., Gerber, M. C., Ewer, M. S., Bianchine, J. R., & Gams, R. A. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1333 · Cited by 269
Progress in Cell Cycle Research
(1997) · Springer eBooks · doi:10.1007/978-1-4615-5371-7 · Cited by 237
Catalytic inhibitors of DNA topoisomerase II
Andoh, T., & Ishida, R. (1998) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(98)00133-x · Cited by 231
Cell line-specific differences in the control of cell cycle progression in the absence of mitosis.
Kung, A. L., Sherwood, S. W., & Schimke, R. T. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.24.9553 · Cited by 222
Cited by
Toward Multi-Targeted Platinum and Ruthenium Drugs—A New Paradigm in Cancer Drug Treatment Regimens?
Kenny, R. G., & Marmion, C. J. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00271 · Cited by 636
Exploiting bacterial DNA gyrase as a drug target: current state and perspectives
Collin, F., Karkare, S., & Maxwell, A. (2011) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-011-3557-z · Cited by 606
Alternative splicing in disease and therapy
Garcia-Blanco, M. A., Baraniak, A. P., & Lasda, E. L. (2004) · Nature Biotechnology · doi:10.1038/nbt964 · Cited by 527
Topoisomerases as anticancer targets
Delgado, J. L., Hsieh, C.-M., Chan, N.-L., & Hiasa, H. (2018) · Biochemical Journal · doi:10.1042/bcj20160583 · Cited by 481
Iron Chelators with Topoisomerase-Inhibitory Activity and Their Anticancer Applications
Rao, V. A. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4877 · Cited by 37
Metadata
- Authors
- Larsen, A. K., Escargueil, A. E., & Skladanowski, A.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2003-08
- Volume
- 99
- Issue
- 2
- Pages
- 167-181
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2010676078
- Cited by
- 398
- References
- 60
- FWCI
- 6.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Catalytic topoisomerase II inhibitors in cancer therapy. https://app.cochat.ai/papers/10.1016/s0163-7258(03)00058-5
- The paper
- Larsen, A. K., Escargueil, A. E., & Skladanowski, A. (2003). Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacology & Therapeutics. https://doi.org/10.1016/s0163-7258(03)00058-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
